Search results
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Zacks via Yahoo Finance· 1 day agoRoche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for...
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
Zacks via Yahoo Finance· 2 years agoThe European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related...
Should You Hold Roche Holding AG (RHHBY)?
Insider Monkey via Yahoo Finance· 1 year agoHarding Loevner, an asset management company, released its “International Equity Strategy” first-quarter 2023 investor letter. A copy of the same can be...
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Zacks via Yahoo Finance· 2 months agoRoche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue...
Roche's (RHHBY) Lunsumio Application Gets Priority Review
Zacks via Yahoo Finance· 2 years agoRoche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory...
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
Zacks via Yahoo Finance· 10 months agoRoche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging...
Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma
Zacks via Yahoo Finance· 1 year agoRoche RHHBY announced that the FDA approved intravenously-administered Lunsumio (mosunetuzumab) for...
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
Zacks via Yahoo Finance· 11 months agoRoche Holding AG’s RHHBY performance in the first half was average, as COVID-19 product related...
Roche (RHHBY) Announces Data on Tecentriq Combo for HCC
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of...
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating...
